JP2018519327A5 - - Google Patents

Download PDF

Info

Publication number
JP2018519327A5
JP2018519327A5 JP2017568200A JP2017568200A JP2018519327A5 JP 2018519327 A5 JP2018519327 A5 JP 2018519327A5 JP 2017568200 A JP2017568200 A JP 2017568200A JP 2017568200 A JP2017568200 A JP 2017568200A JP 2018519327 A5 JP2018519327 A5 JP 2018519327A5
Authority
JP
Japan
Prior art keywords
cancer
combination
combination according
administered
immunotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017568200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519327A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040080 external-priority patent/WO2017004192A1/en
Publication of JP2018519327A publication Critical patent/JP2018519327A/ja
Publication of JP2018519327A5 publication Critical patent/JP2018519327A5/ja
Priority to JP2021143803A priority Critical patent/JP2021183650A/ja
Priority to JP2024100476A priority patent/JP2024111247A/ja
Withdrawn legal-status Critical Current

Links

JP2017568200A 2015-06-29 2016-06-29 治療用組成物、組合せ物および使用の方法 Withdrawn JP2018519327A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021143803A JP2021183650A (ja) 2015-06-29 2021-09-03 治療用組成物、組合せ物および使用の方法
JP2024100476A JP2024111247A (ja) 2015-06-29 2024-06-21 治療用組成物、組合せ物および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186197P 2015-06-29 2015-06-29
US62/186,197 2015-06-29
PCT/US2016/040080 WO2017004192A1 (en) 2015-06-29 2016-06-29 Therapeutic compositions, combinations, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021143803A Division JP2021183650A (ja) 2015-06-29 2021-09-03 治療用組成物、組合せ物および使用の方法

Publications (2)

Publication Number Publication Date
JP2018519327A JP2018519327A (ja) 2018-07-19
JP2018519327A5 true JP2018519327A5 (https=) 2019-07-11

Family

ID=57609144

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017568200A Withdrawn JP2018519327A (ja) 2015-06-29 2016-06-29 治療用組成物、組合せ物および使用の方法
JP2021143803A Withdrawn JP2021183650A (ja) 2015-06-29 2021-09-03 治療用組成物、組合せ物および使用の方法
JP2024100476A Pending JP2024111247A (ja) 2015-06-29 2024-06-21 治療用組成物、組合せ物および使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021143803A Withdrawn JP2021183650A (ja) 2015-06-29 2021-09-03 治療用組成物、組合せ物および使用の方法
JP2024100476A Pending JP2024111247A (ja) 2015-06-29 2024-06-21 治療用組成物、組合せ物および使用の方法

Country Status (13)

Country Link
US (3) US10532056B2 (https=)
EP (2) EP4488265A3 (https=)
JP (3) JP2018519327A (https=)
KR (1) KR102783581B1 (https=)
CN (2) CN114209841A (https=)
AU (3) AU2016286091B2 (https=)
CA (2) CA2991044C (https=)
EA (1) EA201890161A1 (https=)
ES (1) ES2987376T3 (https=)
IL (2) IL322086A (https=)
MX (2) MX389683B (https=)
WO (1) WO2017004192A1 (https=)
ZA (1) ZA201800572B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
AU2014291161B2 (en) 2013-07-18 2018-04-26 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of FGFR inhibitor
EP3091981B1 (en) * 2014-01-09 2021-03-10 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
WO2017044983A1 (en) 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP6664684B1 (ja) * 2017-02-07 2020-03-13 学校法人 埼玉医科大学 がん免疫療法の臨床効果を予測する免疫学的バイオマーカー
AU2018250312C1 (en) 2017-04-07 2024-08-22 Tambo, Inc. Bioorthogonal compositions
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
WO2019018666A1 (en) * 2017-07-21 2019-01-24 University Of North Dakota INHIBITION OF FAK-AKT INTERACTION TO INHIBIT METASTASES
US20210030703A1 (en) * 2018-03-12 2021-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
JP6918204B2 (ja) 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
KR102709127B1 (ko) * 2018-12-27 2024-09-24 하이노바 파마슈티컬스 인코포레이티드 Fak 억제제 및 그 약물 조합물
CN109675040B (zh) * 2018-12-31 2021-07-30 清华大学 治疗乳腺癌的组合物及其应用
TW202035702A (zh) 2019-02-20 2020-10-01 學校法人埼玉醫科大學 評價藉由放射線治療之抗腫瘤免疫效果之末梢血液生物標記
KR20210131387A (ko) * 2019-02-28 2021-11-02 다이호야쿠힌고교 가부시키가이샤 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
TWI757716B (zh) * 2019-04-15 2022-03-11 禾榮科技股份有限公司 微創型中子束產生裝置及微創型中子捕獲治療系統
WO2020230588A1 (ja) 2019-05-10 2020-11-19 富士フイルム株式会社 光照射装置およびセンサー
CN110201171A (zh) * 2019-06-18 2019-09-06 北京大学 Fak抑制剂在治疗常染色体显性遗传多囊肾病中的应用
CN114641310A (zh) * 2019-06-21 2022-06-17 德克萨斯大学系统董事会 治疗癌症和其他疾病的靶向α3β1整合素
WO2021007160A1 (en) * 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
EP4062914A4 (en) 2019-11-18 2024-01-17 Inxmed (Nanjing) Co., Ltd. USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION
US12121519B2 (en) * 2019-11-28 2024-10-22 Inxmed (Nanjing) Co., Ltd. Use of BI853520 in cancer treatment
WO2021154929A1 (en) * 2020-01-31 2021-08-05 Verastem, Inc. Combination therapy for treating abnormal cell growth
EP4101453A4 (en) 2020-02-05 2024-05-15 Inxmed (Nanjing) Co., Ltd. COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
WO2021161994A1 (ja) 2020-02-14 2021-08-19 富士フイルム株式会社 光結合システムおよび光通信デバイス
BR112023000675A2 (pt) * 2020-07-13 2023-04-25 Verastem Inc Terapia de combinação para tratamento de crescimento celular anormal
ES3049298T3 (en) * 2020-08-03 2025-12-16 Inxmed Nanjing Co Ltd Solid form of compound
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
US20240043539A1 (en) * 2020-12-08 2024-02-08 Cornell University Methods of inducing an immunomodulatory tumor response
US20240024317A1 (en) * 2020-12-11 2024-01-25 Materia Therapeutics Inc. Cancer treatment using bosentan in combination with a checkpoint inhibitor
TW202313044A (zh) * 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
JP2024545147A (ja) * 2021-12-10 2024-12-05 ▲應▼世生物科技（南京）有限公司 腫瘍治療の医薬組合せ及び使用
WO2023193705A1 (zh) * 2022-04-07 2023-10-12 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2023246869A1 (zh) * 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
CN119451679A (zh) * 2022-08-24 2025-02-14 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途
EP4585227A4 (en) * 2022-09-05 2025-12-31 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK AND EGFR-TKI INHIBITORS AND USE
WO2024056074A1 (zh) * 2022-09-16 2024-03-21 应世生物科技(南京)有限公司 Fak抑制剂及拓扑异构酶抑制剂的药物组合及用途
CN119947725A (zh) * 2022-09-30 2025-05-06 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途
WO2024158840A2 (en) * 2023-01-24 2024-08-02 Simcha IL-18, Inc. Methods and compositions for combination therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US20030009158A1 (en) 2001-07-09 2003-01-09 Perricone Nicholas V. Skin treatments using blue and violet light
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
FI20030976L (fi) 2003-06-30 2004-12-31 M Real Oyj Päällystetty pohjapaperi ja menetelmä päällystetyn pohjapaperin valmistamiseksi
US20090022846A1 (en) 2004-06-30 2009-01-22 Helle Wittorff Chewing Gum Comprising Flavor Emulsion
EA017405B9 (ru) * 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
EP2727909A1 (en) 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
WO2009153589A1 (en) 2008-06-17 2009-12-23 Astrazeneca Ab Pyridine compounds
US20140155410A1 (en) 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
EP2726079A4 (en) 2011-06-28 2014-12-17 Glaxosmithkline Ip No 2 Ltd ADMINISTRATIVE AND TREATMENT PROCEDURES
EP2903644A4 (en) * 2012-10-05 2016-03-09 Cerulean Pharma Inc TREATMENT OF CANCER
US20150118247A1 (en) * 2013-10-25 2015-04-30 Nodality, Inc. Methods and compositions for immunomodulation
WO2015063647A1 (en) 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
WO2015120289A1 (en) 2014-02-07 2015-08-13 Verastem, Inc. Methods and compositions for treating abnormal cell growth
WO2017201043A1 (en) 2016-05-16 2017-11-23 Concert Pharmaceuticals, Inc. Combination therapy for treating cancer

Similar Documents

Publication Publication Date Title
JP2018519327A5 (https=)
KR102333658B1 (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
Kim et al. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
JP2018508512A5 (https=)
JP2018518454A5 (https=)
JP2020532537A5 (https=)
JP2025185043A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
JP2016516800A5 (https=)
JP2022512851A5 (https=)
Froesch et al. Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Jiang et al. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
JPWO2022270524A5 (https=)
HK1225995A1 (zh) 用於治疗或缓解高龄或晚期癌症患者的药物组合物
Bironzo et al. Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?
Benitez et al. Hepatic intra-arterial chemotherapy with immunotherapy in NSCLC
JP2024519450A5 (https=)
TW202317183A (zh) 藉由併用ｃｄ４７抑制物質、免疫檢查點抑制物質及標準療法之癌症治療法
NZ739490B2 (en) Therapeutic compositions, combinations, and methods of use
TW201922292A (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
JPWO2022270523A5 (https=)
EP4637731A1 (en) Combination therapy for treating cancer
CN117460534A (zh) 基于cd47抑制物质、免疫检查点抑制物质和标准疗法的联用的癌症治疗方法
HK40125832A (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
NZ739490A (en) Therapeutic compositions, combinations, and methods of use
Lakhani et al. A First-in-Human Study of ALX148: CD47 Blockade to Enhance Innate and Adaptive Immunity for Advanced Solid Tumor Malignancy and Non-Hodgkin Lymphoma